NEULAND LABS Fact Sheet, NEULAND LABS Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS Fact Sheet   (NELB)


Watch Now: One Stock Crorepati Replay is Available Now


Here is the latest financial fact sheet of NEULAND LABS. For more details, see the NEULAND LABS quarterly results and NEULAND LABS share price and chart. For a sector overview, read our pharmaceuticals sector report.

NEULAND LABS Price History

Price Rs 1,187.8
Mkt Cap Rs m 15,239
Vol '000 0.4
P/E X 23.9
P/CF X 12.7
EPS (TTM) Rs 49.7
1 Day % 0.8
No. of shares m 12.83
1 Week % 13.3
1 Month % 10.7
1 Year % -44.6
52 week H/L Rs 2,275.0/965.9
As on Jul 1, 2022 (Close)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

NEULAND LABS Financials

No. of Mths
Year Ending
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
12
Mar-20
*
12
Mar-21
*
5-Yr Chart
Click to enlarge
NEULAND LABS EQUITY SHARE DATA
High Rs1,5571,6808287542,350 
Low Rs678680431247260 
Sales per share (Unadj.) Rs641.9592.0519.7594.5730.3 
Earnings per share (Unadj.) Rs52.813.612.812.662.8 
Diluted earnings per shareRs36.59.412.812.662.8 
Cash flow per share (Unadj.) Rs74.438.533.037.093.8 
Dividends per share (Unadj.) Rs001.202.005.00 
Adj. dividends per shareRs0.000.001.202.005.00 
Avg Dividend yield %000.20.40.4 
Book value per share (Unadj.) Rs264.4278.4545.1553.4613.0 
Adj. book value per shareRs183.0192.7545.1553.4613.0 
Shares outstanding (eoy) m8.888.8812.8312.8312.83 
Bonus / Rights / Conversions  00000 
Price / Sales ratio x1.72.01.20.81.8 
Avg P/E ratio x21.286.949.139.620.8 
P/CF ratio (eoy) x15.030.719.113.513.9 
Price / Book Value ratio x4.24.21.20.92.1 
Dividend payout %009.415.88.0 
Avg Mkt Cap Rs m9,93010,4838,0786,42116,746 
No. of employees `000NANANANANA 
Total wages/salary Rs m9271,0301,1051,2361,497 
Avg. sales/employee Rs Th00000 
Avg. wages/employee Rs Th00000 
Avg. net profit/employee Rs Th00000 
NEULAND LABS INCOME DATA
Net Sales Rs m5,7005,2576,6687,6279,369 
Other income Rs m12453539161 
Total revenues Rs m5,7125,3026,7037,6669,530 
Gross profit Rs m1,0635045841,0191,468 
Depreciation Rs m192221259313397 
Interest Rs m211189157216179 
Profit before tax Rs m6721392035291,053 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m2031939367247 
Profit after tax Rs m469121164162806 
Gross profit margin %18.79.68.813.415.7 
Effective tax rate %30.213.419.269.423.5 
Net profit margin %8.22.32.52.18.6 
NEULAND LABS BALANCE SHEET DATA
Current assets Rs m3,7504,4724,5355,1525,496 
Current liabilities Rs m2,8563,6693,2703,5763,685 
Net working cap to sales %15.715.319.020.719.3 
Current ratio x1.31.21.41.41.5 
Inventory Days Days4042373726 
Debtors Days Days1,1601,347898909848 
Net fixed assets Rs m5,1056,2426,7697,1587,752 
Share capital Rs m9090129129129 
"Free" reserves Rs m2,2582,3826,8646,9717,736 
Net worth Rs m2,3482,4726,9937,1007,865 
Long term debt Rs m2981,035607774881 
Total assets Rs m8,85610,71411,30412,31013,248 
Interest coverage x4.21.72.33.56.9 
Debt to equity ratio x0.10.40.10.10.1 
Sales to assets ratio x0.60.50.60.60.7 
Return on assets %7.72.92.83.17.4 
Return on equity %20.04.92.42.310.3 
Return on capital %33.49.44.79.514.1 
Exports to sales %76.475.072.568.077.8 
Imports to sales %15.719.125.220.929.5 
Exports (fob) Rs m4,3563,9444,8355,1877,292 
Imports (cif) Rs m8971,0021,6811,5932,765 
Fx inflow Rs m4,3563,9444,8355,1877,292 
Fx outflow Rs m1,0141,0021,6811,5932,765 
Net fx Rs m3,3422,9423,1543,5944,527 
NEULAND LABS CASH FLOW
From Operations Rs m 387 113 699 573 1,894 
From Investments Rs m -421 -1,163 -772 -487 -844 
From Financial Activity Rs m -1 1,049 120 -55 -1,137 
Net Cashflow Rs m -35 -2 47 33 -88 
* Results Consolidated
Source: Accord Fintech, Equitymaster

Share Holding

Promoters 36.2%
Institution 23.6%
Non-Institution 40.2%
Total 100.0%
Free Float 63.8%
Pledged promoter holdings 0.0%
Shareholding as on Mar 2022
 

Company Information

Regd Off 11th Floor (5th Office Level), Phoenix I V Y Building Plot No.573 A- I I I, Road No. 82 Jubilee Hills, Hyderabad - 500033
E-mail ir@neulandlabs.com Web www.neulandlabs.com
Tel 040-67611600 Fax 040-30211602
Sector PHARMACEUTICALS Group Private sector
Tr Agent K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.), Karvy Selenium Tower B Plot 31-32, Gachibowli Financial District, Nanakramguda
CHM: Davuluri Rama Mohan Rao COMP SEC: Sarada Bhamidipati YEAR OF INC: 1984 BSE CODE: 524558 FV (Rs): 10 DIV YIELD (%): 0.4

More Pharmaceuticals Company Fact Sheets:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    

Compare NEULAND LABS With:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    




Today's Market

Sensex Ends 111 Points Lower, Nifty Holds 15,750; ONGC, Reliance Crash, while ITC & Bajaj Twins Gain 4%(Closing)

After opening the day deep in the red, Indian share markets slowly recovered most of their losses and ended on a flat note.

Views on news

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

Best Monopoly Stocks to Own in 2022 Views On News (Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

The One Smallcap Stock I'll Recommend Now (Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

Wait! Don't Buy the Smallcap 'Dip' Just Yet (Profit Hunter)

Jun 20, 2022

Why this may not be the best time to buy smallcaps.

5 Consistent Compounding Stocks Available at Discount. Time to Buy? (Views On News)

Jun 22, 2022

The good side of a market correction? Investors get consistent compounding stocks at a discount.

Looking for Value Stocks Amid Volatile Times? Consider These 5 Stocks (Views On News)

Jun 20, 2022

These value stocks have the potential to deliver good returns in the long run. Watch out for them.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NEULAND LABS

NEULAND LABS 8-QTR ANALYSIS

COMPARE NEULAND LABS WITH

MARKET STATS